Literature DB >> 22006982

Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis.

Stephanie B Syc1, Shiv Saidha, Scott D Newsome, John N Ratchford, Michael Levy, E'tona Ford, Ciprian M Crainiceanu, Mary K Durbin, Jonathan D Oakley, Scott A Meyer, Elliot M Frohman, Peter A Calabresi.   

Abstract

Post-mortem ganglion cell dropout has been observed in multiple sclerosis; however, longitudinal in vivo assessment of retinal neuronal layers following acute optic neuritis remains largely unexplored. Peripapillary retinal nerve fibre layer thickness, measured by optical coherence tomography, has been proposed as an outcome measure in studies of neuroprotective agents in multiple sclerosis, yet potential swelling during the acute stages of optic neuritis may confound baseline measurements. The objective of this study was to ascertain whether patients with multiple sclerosis or neuromyelitis optica develop retinal neuronal layer pathology following acute optic neuritis, and to systematically characterize such changes in vivo over time. Spectral domain optical coherence tomography imaging, including automated retinal layer segmentation, was performed serially in 20 participants during the acute phase of optic neuritis, and again 3 and 6 months later. Imaging was performed cross-sectionally in 98 multiple sclerosis participants, 22 neuromyelitis optica participants and 72 healthy controls. Neuronal thinning was observed in the ganglion cell layer of eyes affected by acute optic neuritis 3 and 6 months after onset (P < 0.001). Baseline ganglion cell layer thicknesses did not demonstrate swelling when compared with contralateral unaffected eyes, whereas peripapillary retinal nerve fibre layer oedema was observed in affected eyes (P = 0.008) and subsequently thinned over the course of this study. Ganglion cell layer thickness was lower in both participants with multiple sclerosis and participants with neuromyelitis optica, with and without a history of optic neuritis, when compared with healthy controls (P < 0.001) and correlated with visual function. Of all patient groups investigated, those with neuromyelitis optica and a history of optic neuritis exhibited the greatest reduction in ganglion cell layer thickness. Results from our in vivo longitudinal study demonstrate retinal neuronal layer thinning following acute optic neuritis, corroborating the hypothesis that axonal injury may cause neuronal pathology in multiple sclerosis. Further, these data provide evidence of subclinical disease activity, in both participants with multiple sclerosis and with neuromyelitis optica without a history of optic neuritis, a disease in which subclinical disease activity has not been widely appreciated. No pathology was seen in the inner or outer nuclear layers of eyes with optic neuritis, suggesting that retrograde degeneration after optic neuritis may not extend into the deeper retinal layers. The subsequent thinning of the ganglion cell layer following acute optic neuritis, in the absence of evidence of baseline swelling, suggests the potential utility of quantitative optical coherence tomography retinal layer segmentation to monitor neuroprotective effects of novel agents in therapeutic trials.

Entities:  

Mesh:

Year:  2011        PMID: 22006982      PMCID: PMC3281477          DOI: 10.1093/brain/awr264

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  44 in total

1.  Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers.

Authors:  Tongguang Wang; Myoung-Hwa Lee; Tory Johnson; Rameeza Allie; Lina Hu; Peter A Calabresi; Avindra Nath
Journal:  J Neurosci       Date:  2010-04-07       Impact factor: 6.167

2.  T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.

Authors:  Robert C Axtell; Brigit A de Jong; Katia Boniface; Laura F van der Voort; Roopa Bhat; Patrizia De Sarno; Rodrigo Naves; May Han; Franklin Zhong; Jim G Castellanos; Robert Mair; Athena Christakos; Ilan Kolkowitz; Liat Katz; Joep Killestein; Chris H Polman; René de Waal Malefyt; Lawrence Steinman; Chander Raman
Journal:  Nat Med       Date:  2010-03-28       Impact factor: 53.440

Review 3.  Optical coherence tomography: a window into the mechanisms of multiple sclerosis.

Authors:  Elliot M Frohman; James G Fujimoto; Teresa C Frohman; Peter A Calabresi; Gary Cutter; Laura J Balcer
Journal:  Nat Clin Pract Neurol       Date:  2008-12

4.  Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis.

Authors:  R T Naismith; N T Tutlam; J Xu; J B Shepherd; E C Klawiter; S-K Song; A H Cross
Journal:  Neurology       Date:  2009-07-07       Impact factor: 9.910

5.  Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis.

Authors:  Bryn M Burkholder; Benjamin Osborne; Michael J Loguidice; Esther Bisker; Teresa C Frohman; Amy Conger; John N Ratchford; Christina Warner; Clyde E Markowitz; Dina A Jacobs; Steven L Galetta; Gary R Cutter; Maureen G Maguire; Peter A Calabresi; Laura J Balcer; Elliot M Frohman
Journal:  Arch Neurol       Date:  2009-11

6.  Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies.

Authors:  J N Ratchford; M E Quigg; A Conger; T Frohman; E Frohman; L J Balcer; P A Calabresi; D A Kerr
Journal:  Neurology       Date:  2009-07-28       Impact factor: 9.910

Review 7.  Imaging outcomes for neuroprotection and repair in multiple sclerosis trials.

Authors:  Frederik Barkhof; Peter A Calabresi; David H Miller; Stephen C Reingold
Journal:  Nat Rev Neurol       Date:  2009-05       Impact factor: 42.937

8.  Thickness of receptor and post-receptor retinal layers in patients with retinitis pigmentosa measured with frequency-domain optical coherence tomography.

Authors:  Donald C Hood; Christine E Lin; Margot A Lazow; Kirsten G Locke; Xian Zhang; David G Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-11-14       Impact factor: 4.799

9.  Optical coherence tomography and disease subtype in multiple sclerosis.

Authors:  M Pulicken; E Gordon-Lipkin; L J Balcer; E Frohman; G Cutter; P A Calabresi
Journal:  Neurology       Date:  2007-11-27       Impact factor: 9.910

10.  Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography.

Authors:  Ou Tan; Vikas Chopra; Ake Tzu-Hui Lu; Joel S Schuman; Hiroshi Ishikawa; Gadi Wollstein; Rohit Varma; David Huang
Journal:  Ophthalmology       Date:  2009-09-10       Impact factor: 12.079

View more
  127 in total

1.  Functional-structural correlations in the afferent visual pathway in pediatric demyelination.

Authors:  E Ann Yeh; Ruth Ann Marrie; Y Arun Reginald; J Raymond Buncic; Austin E Noguera; Julia O'Mahony; Jean K Mah; Brenda Banwell; Fiona Costello
Journal:  Neurology       Date:  2014-10-31       Impact factor: 9.910

2.  Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning.

Authors:  Elias S Sotirchos; Angeliki Filippatou; Kathryn C Fitzgerald; Sara Salama; Santiago Pardo; Jiangxia Wang; Esther Ogbuokiri; Norah J Cowley; Nicole Pellegrini; Olwen C Murphy; Maureen A Mealy; Jerry L Prince; Michael Levy; Peter A Calabresi; Shiv Saidha
Journal:  Mult Scler       Date:  2019-07-31       Impact factor: 6.312

3.  From Imaging the Brain to Imaging the Retina: Optical Coherence Tomography (OCT) in Schizophrenia.

Authors:  Carlos Schönfeldt-Lecuona; Thomas Kregel; Arno Schmidt; Elmar H Pinkhardt; Florian Lauda; Jan Kassubek; Bernhard J Connemann; Roland W Freudenmann; Maximilian Gahr
Journal:  Schizophr Bull       Date:  2015-06-05       Impact factor: 9.306

4.  Evaluation of inner retinal layers in eyes with temporal hemianopic visual loss from chiasmal compression using optical coherence tomography.

Authors:  Mário L R Monteiro; Kenzo Hokazono; Danilo B Fernandes; Luciana V F Costa-Cunha; Rafael M Sousa; Ali S Raza; Diane L Wang; Donald C Hood
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-24       Impact factor: 4.799

5.  Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.

Authors:  Julia Button; Omar Al-Louzi; Andrew Lang; Pavan Bhargava; Scott D Newsome; Teresa Frohman; Laura J Balcer; Elliot M Frohman; Jerry Prince; Peter A Calabresi; Shiv Saidha
Journal:  Neurology       Date:  2017-01-11       Impact factor: 9.910

Review 6.  Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials.

Authors:  Maria Pia Sormani; Matteo Pardini
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

7.  Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis.

Authors:  Angeliki G Filippatou; Jeffrey Lambe; Elias S Sotirchos; Kathryn C Fitzgerald; Andrew Aston; Olwen C Murphy; Nicole Pellegrini; Nicholas Fioravante; Hunter Risher; Esther Ogbuokiri; Ohemaa Kwakyi; Brandon Toliver; Simidele Davis; Nicholas Luciano; Ciprian Crainiceanu; Jerry L Prince; Ellen M Mowry; Peter A Calabresi; Shiv Saidha
Journal:  Mult Scler       Date:  2020-04-16       Impact factor: 6.312

Review 8.  Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis.

Authors:  Josefine Britze; Gorm Pihl-Jensen; Jette Lautrup Frederiksen
Journal:  J Neurol       Date:  2017-05-31       Impact factor: 4.849

9.  Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.

Authors:  Caspar B Seitz; Amgad Droby; Lena Zaubitzer; Julia Krämer; Mathieu Paradis; Luisa Klotz; Heinz Wiendl; Sergiu Groppa; Sven G Meuth; Frauke Zipp; Vinzenz Fleischer
Journal:  J Neurol       Date:  2018-08-02       Impact factor: 4.849

Review 10.  [Optical coherence tomography in neuromyelitis optica spectrum disorders].

Authors:  F C Oertel; H Zimmermann; A U Brandt; F Paul
Journal:  Nervenarzt       Date:  2017-12       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.